{
    "organizations": [],
    "uuid": "02c0bd70fb7a205f0e78fc92181306095de72177",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cti-biopharma-announces-launch-of/brief-cti-biopharma-announces-launch-of-follow-on-offering-idUSASB0C3WS",
    "ord_in_thread": 0,
    "title": "BRIEF-CTI Biopharma Announces Launch Of Follow-On Offering",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) -\n* CTI BIOPHARMA ANNOUNCES LAUNCH OF FOLLOW-ON OFFERING * CTI BIOPHARMA CORP - INTENDS TO USE NET PROCEEDS OF OFFERING TO COMPLETE PAC203 CLINICAL TRIAL, COMPLETE REVIEW OF PACRITINIB MAA BY EMA, AMONG OTHERS Source text for Eikon:\n ",
    "published": "2018-02-05T21:38:00.000+02:00",
    "crawled": "2018-02-07T00:20:13.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "cti",
        "biopharma",
        "announces",
        "launch",
        "offering",
        "cti",
        "biopharma",
        "corp",
        "intends",
        "use",
        "net",
        "proceeds",
        "offering",
        "complete",
        "pac203",
        "clinical",
        "trial",
        "complete",
        "review",
        "pacritinib",
        "maa",
        "ema",
        "among",
        "others",
        "source",
        "text",
        "eikon"
    ]
}